Nasal Decongestant PE

Manufacturer
Bi-Mart | ELYSIUM PHARMACEUTICALS LIMITED
Effective date
2025-03-01
Label type
HUMAN OTC DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-06-01 00:57:52

Label at a glance#

ProductNasal Decongestant PE
Active ingredientPHENYLEPHRINE HYDROCHLORIDE
Label structure16 sections

Indications and uses

temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies temporarily relieves sinus congestion and pressure

Dosage and administration

adults and children 12 years and over: take 1 tablet every 4 hours. Do not take more than 6 tablets in 24 hours. children under 12 years: ask a doctor

Storage and handling

each tablet contains: phosphorus 10 mg store between 20°-25°C (68°-77°F) protect from excessive moisture DO NOT USE IF PRINTED SEAL UNDER CAP IS MISSING OR DAMAGED

Label contents#

Full prescribing information#

Active Ingredient (in each tablet)

OTC - ACTIVE INGREDIENT SECTION

Phenylephrine HCl 10mg

Purpose

OTC - PURPOSE SECTION

Nasal decongestant

Uses

INDICATIONS & USAGE SECTION

  • temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies
  • temporarily relieves sinus congestion and pressure

Warnings

WARNINGS SECTION

Do not use ifyou are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product.

Ask a doctor before use if you have

OTC - ASK DOCTOR SECTION

  • heart disease
  • high blood pressure 
  • thyroid disease
  • diabetes
  • trouble urinating due to an enlarged prostate gland.

OTC - WHEN USING SECTION

When using this product do not exceed recommended dose.

Stop use and ask a doctor if

OTC - STOP USE SECTION

  • nervousness, dizziness, or sleeplessness occur
  • symptoms do not improve within 7 days or occur with a fever.

OTC - PREGNANCY OR BREAST FEEDING SECTION

If pregnant or breast-feeding,ask a health professional before use.

OTC - KEEP OUT OF REACH OF CHILDREN SECTION

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center (1-800 222-1222) right away.

Directions

DOSAGE & ADMINISTRATION SECTION

  • adults and children 12 years and over:take 1 tablet every 4 hours. Do not take more than 6 tablets in 24 hours.
  • children under 12 years:ask a doctor

Other Information

STORAGE AND HANDLING SECTION

  • each tablet contains:phosphorus 10 mg
  • store between 20°-25°C (68°-77°F)
  • protect from excessive moisture
  • DO NOT USE IF PRINTED SEAL UNDER CAP IS MISSING OR DAMAGED

Inactive Ingredients

INACTIVE INGREDIENT SECTION

Crosscarmellose Soidum, Colloidal Silicon Dioxide, Dicalcium Phosphate, FD&C Red 40, Magnesium Stearate, Microcrystalline Cellulose

Questions?

OTC - QUESTIONS SECTION

call toll free 1-844-912-4012

SPL UNCLASSIFIED SECTION

Distributed by:

BI-MART

Eugene, OR 97402

PRINCIPAL DISPLAY PANEL-36 Count

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 37835-651-36

Compare to the active ingredients in Sudafed PE® Sinus Congestion*

NON-DROWSY

NASAL DECONGESTANT PE

Phenylephrine HCl 10 mg

Relieves: Nasal & Sinus Congestion & Sinus Pressure

36 Tablets

*This product is not manufactured or distributed by the owner of the registered trademark Sudafed PE ®Sinus Congestion.

labellabel

PRINCIPAL DISPLAY PANEL-100 Count

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 37835-651-01

Compare to the active ingredients in Sudafed PE® Sinus Congestion*

NON-DROWSY

NASAL DECONGESTANT PE

Phenylephrine HCl 10 mg

Relieves: Nasal & Sinus Congestion & Sinus Pressure

100 Tablets

*This product is not manufactured or distributed by the owner of the registered trademark Sudafed PE ®Sinus Congestion.

labellabel

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1049182phenylephrine HCl 10 MG Oral TabletPSN1
1049182phenylephrine hydrochloride 10 MG Oral TabletSCD1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
PHENYLEPHRINE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
37835-651-01Nasal Decongestant PE100 in 1 BOTTLETABLET1001
37835-651-36Nasal Decongestant PE36 in 1 BOTTLETABLET361

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
37835-651NASAL DECONGESTANT PE (PHENYLEPHRINE HYDROCHLORIDE) TABLET [BI-MART]1Current NDC, 2 package rows20250327_d208cb6f-e142-4aa3-959b-e6b601df76c1.zip

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 9 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
37835-65137835-651-36, 37835-651-01

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 7 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Nasal Decongestant PEPHENYLEPHRINE HYDROCHLORIDEBi-Martd208cb6f-e142-4aa3-959b-e6b601df76c12025-03-01WarningsExact identifier
ndc (package): 37835-651-36
ndc (package): 37835-651-01
ndc (product): 37835-651
ndc11 (package): 37835065136
ndc11 (package): 37835065101
spl id: 3127723a-459d-0ab2-e063-6394a90ad329
spl set id: d208cb6f-e142-4aa3-959b-e6b601df76c1

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.